CollabRx Teams with MedPage Today to Introduce Digital Tool for Patient-Specific Genomic Approaches to Cancer Treatment

Tegal Corporation / CollabRx, Inc.James M. Karis, Co-CEO(650) 352-4790orRobert Ferri Partners, LLC, Investor Relations for Tegal/CollabRxRobert Ferri(415) 575-1589 (direct)orEveryday Health, Inc.Jennifer Perciballi, Vice President, Public Relations(646) 728-9777 office(646) 476-1245 mobile

Tegal Corporation (NASDAQ: TGAL) today announced that its recently acquired CollabRx, Inc., subsidiary signed an exclusive license agreement to provide a version of its proprietary Therapy Finder™ tool to , Everyday Health, Inc.’s rapidly growing online site that serves 96% of all oncologists and 1.6 million monthly online unique users.

CollabRx is a cloud-based genomic information company that enables physicians to take into account a tumor’s genetic profile when considering targeted therapies in patient-specific cancer treatments. To be launched today exclusively at as , the CollabRx tool leverages recent years’ dramatic increase in tumor genetic data, which in turn has resulted in a parallel increase in the development of cancer therapies that target specific genetic profiles.

CollabRx has developed clinical advisory networks, expert systems, proprietary tools and processes, and a pipeline of commercial data products and applications (“apps”). CollabRx Therapy Finders™ are web-based apps that serve as one type of user interface to access proprietary CollabRx content, which is dynamically updated and organized in a knowledgebase that includes information on molecular diagnostics, medical tests, clinical trials, drugs, biologics and other information relevant for cancer treatment planning. CollabRx content is supported by a network of over 50 of the top clinical practitioners in the United States.

“will bring CollabRx proprietary content to registered physicians of , which attracted over 1.6 million unique visitors in June 2012 (comScore), making it one of the top healthcare professional websites in the U.S. will be available initially as a free digital decision-support service focusing on treatment of lung cancer. Subsequently on a rolling basis, is to deliver information on treatment of melanoma, colorectal cancer and breast cancer.

is a free service to help physicians choose well for their patients. Everyday Health and will offer sponsorships and lead generation tools to major healthcare companies in connection with this initiative. In addition to licence fees, a portion of the revenue generated by sponsorships is to be shared with CollabRx.

“The medical doctors and scientists at CollabRx have created this breakthrough tool, and has the strongest platform to reach physicians and help change cancer patient outcomes,” said James Karis, CEO of CollabRx, Inc. and Co-CEO of Tegal Corporation. “The CollabRx strategy is to develop partnerships with key players that have the greatest reach to multiple health care market segments. We are excited to be able to announce our first partnership with the leading digital resource for healthcare professionals.”

“ partnership with CollabRx illustrates our commitment to providing innovative and state-of-the-art tools for physicians,” explained , CEO and Co-Founder Everyday Health, Inc. “’ provides the community of oncologists free access to medical and scientific advances in genomic medicine to better inform their treatment planning for their patients.”

The companion announcement from Everyday Health is available on Everyday Health, Inc.’s corporate website: and the CollabRx website.

Since its founding in 1972, Tegal Corporation has been dedicated to the development and application of emerging technologies. For 40 years, Tegal’s process and equipment know-how has been incorporated in devices fabricated by some of the world’s leading semiconductor and MEMS companies, including Tegal’s one-time parent, Motorola. Now entering its fifth decade, Tegal has committed its future to the CollabRx vision of “Informing Next Generation Healthcare”. Please visit us on the web at .

CollabRx is a recognized leader in “cloud-based” expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be found at .

MedPage Today is the fastest growing news organization serving healthcare professionals (comScore.)The company's daily, peer-reviewed news coverage delivered via the web and several mobile applications allows healthcare professionals to put breaking medical news into practice. MedPage Today also offers coverage of health conferences from around the world in almost any specialty, and physicians can access live video interviews and dialogues to encourage conversation and better health outcomes. Medpage Today had over 1.6 million unique visitors in June 2012(comScore), making it one of the top HCP website in the U.S.

is the leading new media health company. Attracting 38 million people monthly through its popular websites, mobile applications, and social media presence, Everyday Health inspires consumers to live healthier lives and helps doctors make more informed decisions for their patients. Everyday Health reaches an additional one million viewers per episode through its weekly TV series on ABC stations. The Company’s broad portfolio of products spans the health spectrum, from in-depth medical content for condition prevention and management to healthy lifestyle offerings. Everyday Health was founded in 2002 by CEO, Ben Wolin, and President, Mike Keriakos.

Source: comScore Media Metrix; comScore Video Metrix; Facebook Insights; Twitter.

This press release contains forward-looking statements that may include statements regarding the intent, belief or current expectations of Tegal, CollabRx and their respective management. Forward looking statements include statements about the benefits and advantages of the acquisition for Tegal and CollabRx. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including but not limited to the risk that the acquisition will not close as the transaction is subject to certain closing conditions. In addition, if and when the transaction is closed, there will be risks and uncertainties related to Tegal’s ability to integrate CollabRx successfully, the risk that the anticipated benefits from the acquisition may not be fully realized or may take longer to realize than expected; and competition and its effect on the combined company’s performance. Additional factors that may affect future results are contained in the SEC filings for Tegal, including but not limited to Tegal’s Annual Report on Form 10-K for the year ended March 31, 2012. Tegal and CollabRx each disclaim any obligation to update and revise statements contained in this release based on new information or otherwise.

Since the July 12 acquisition of CollabRx, Tegal has announced that it intends to continue to operate under its current name and ticker symbol for the time being, but plans to seek stockholder approval at its upcoming annual meeting on September 25, 2012 for an amendment to its Certificate of Incorporation, changing its corporate name to CollabRx, Inc.

Photos/Multimedia Gallery Available: